Application of an immune-magnetic cell sorting method for CD138-positive plasma cells in FISH analysis of multiple myeloma

被引:10
作者
Shin, S. Y. [1 ]
Jang, S. [1 ]
Park, C. -J. [1 ]
Chi, H. -S. [1 ]
Lee, J. -H. [2 ]
Lee, J. H. [2 ]
Lee, K. H. [2 ]
Suh, C. [2 ]
Lim, S. E. [3 ]
Seo, E. -J. [1 ]
机构
[1] Univ Ulsan, Coll Med, Dept Lab Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Dept Internal Med, Seoul, South Korea
[3] Asan Med Ctr, Ctr Med Genet, Seoul 138736, South Korea
关键词
Multiple myeloma; FISH; immune-magnetic sorting; plasma cell purification; IN-SITU HYBRIDIZATION; CYTOGENETIC ABERRATIONS; PROGNOSTIC-FACTOR; STAGING SYSTEM; ABNORMALITIES; SURVIVAL; THERAPY;
D O I
10.1111/j.1751-553X.2012.01433.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Interphase fluorescence in situ hybridization (FISH) analysis of multiple myeloma (MM) may indiscriminately count signals of nonplasma cells, thus decreasing specificity and sensitivity. We aimed to evaluate the usefulness of an immune-magnetic sorting method for plasma cells in FISH analysis of MM and define optimal sample preparation conditions. Methods: Plasma cells were purified using EasySep (R) CD138 Positive Selection Cocktail and Magnetic Nanoparticles (Invitrogen). We compared FISH results with and without plasma cell purification for three sample preparation methods: direct harvest, 24-h culture, and 96-h culture with interleukin-4 in five newly diagnosed MM patients. Archived fixed bone marrow cells of 17 MM patients were also studied. Results: The percentage of abnormal cells identified was significantly higher with plasma cell purification than without purification (median, 88.0%; range, 84.0-100.0%vs. 15.0%, 12.5-29.5%, respectively). The three sample preparation methods showed comparable results. Immune-magnetic sorting also significantly increased the percentage of abnormal cells identified in FISH analysis of archived fixed bone marrow cells (P < 0.001). Conclusions: Immune-magnetic CD138-positive cell sorting significantly increased the percentage of abnormal cells identified in FISH analysis of MM samples for all sample preparation methods. This method could also be applied for retrospective FISH analysis of archived fixed bone marrow cells.
引用
收藏
页码:541 / 546
页数:6
相关论文
共 22 条
  • [1] Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
    Avet-Loiseau, H
    Facon, T
    Grosbois, B
    Magrangeas, F
    Rapp, MJ
    Harousseau, JL
    Minvielle, S
    Bataille, R
    [J]. BLOOD, 2002, 99 (06) : 2185 - 2191
  • [2] Role of genetics in prognostication in myeloma
    Avet-Loiseau, Herve
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (04) : 625 - 635
  • [3] Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
    Avet-Loiseau, Herve
    Attal, Michel
    Moreau, Philippe
    Charbonnel, Catherine
    Garban, Frederic
    Hulin, Cyrille
    Leyvraz, Serge
    Michallet, Mauricette
    Yakoub-Agha, Ibrahim
    Garderet, Laurent
    Marit, Gerald
    Michaux, Lucienne
    Voillat, Laurent
    Renaud, Marc
    Grosbois, Bernard
    Guillerm, Gaelle
    Benboubker, Lotfi
    Monconduit, Mathieu
    Thieblemont, Catherine
    Casassus, Philippe
    Caillot, Denis
    Stoppa, Anne-Marie
    Sotto, Jean-Jacques
    Wetterwald, Marc
    Dumontet, Charles
    Fuzibet, Jean-Gabriel
    Azais, Isabelle
    Dorvaux, Veronique
    Zandecki, Marc
    Bataille, Regis
    Minvielle, Stephane
    Harousseau, Jean-Luc
    Facon, Thierry
    Mathiot, Claire
    [J]. BLOOD, 2007, 109 (08) : 3489 - 3495
  • [4] p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
    Chang, H
    Qi, C
    Yi, QL
    Reece, D
    Stewart, AK
    [J]. BLOOD, 2005, 105 (01) : 358 - 360
  • [5] DEWALD GW, 1985, BLOOD, V66, P380
  • [6] Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
    Dimopoulos, Meletios
    Kyle, Robert
    Fermand, Jean-Paul
    Rajkumar, S. Vincent
    San Miguel, Jesus
    Chanan-Khan, Asher
    Ludwig, Heinz
    Joshua, Douglas
    Mehta, Jayesh
    Gertz, Morie
    Avet-Loiseau, Herve
    Beksac, Meral
    Anderson, Kenneth C.
    Moreau, Philippe
    Singhal, Seema
    Goldschmidt, Hartmut
    Boccadoro, Mario
    Kumar, Shaji
    Giralt, Sergio
    Munshi, Nikhil C.
    Jagannath, Sundar
    [J]. BLOOD, 2011, 117 (18) : 4701 - 4705
  • [7] DRACH J, 1995, CANCER RES, V55, P3854
  • [8] Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
    Facon, T
    Avet-Loiseau, H
    Guillerm, G
    Moreau, P
    Geneviève, F
    Zandecki, M
    Laï, JL
    Leleu, X
    Jouet, JP
    Bauters, F
    Harousseau, JL
    Bataille, R
    Mary, JY
    [J]. BLOOD, 2001, 97 (06) : 1566 - 1571
  • [9] Clinical and biologic implications of recurrent genomic aberrations in myeloma
    Fonseca, R
    Blood, E
    Rue, M
    Harrington, D
    Oken, MM
    Kyle, RA
    Dewald, GW
    Van Ness, B
    Van Wier, SA
    Henderson, KJ
    Bailey, RJ
    Greipp, PR
    [J]. BLOOD, 2003, 101 (11) : 4569 - 4575
  • [10] Fonseca Rafael, 2004, Cancer Research, V64, P1546, DOI 10.1158/0008-5472.CAN-03-2876